WO2002058694A3 - Method of treating hematologic tumors and cancers using beta lapachone - Google Patents

Method of treating hematologic tumors and cancers using beta lapachone Download PDF

Info

Publication number
WO2002058694A3
WO2002058694A3 PCT/US2001/049946 US0149946W WO02058694A3 WO 2002058694 A3 WO2002058694 A3 WO 2002058694A3 US 0149946 W US0149946 W US 0149946W WO 02058694 A3 WO02058694 A3 WO 02058694A3
Authority
WO
WIPO (PCT)
Prior art keywords
phase drug
cancers
combination
hematologic tumors
multiple myeloma
Prior art date
Application number
PCT/US2001/049946
Other languages
French (fr)
Other versions
WO2002058694A9 (en
WO2002058694A2 (en
Inventor
Arthur B Pardee
Kenneth Anderson
Deepak Gupta
Chiang Li
Youzhi Li
Original Assignee
Dana Farber Cancer Inst Inc
Arthur B Pardee
Kenneth Anderson
Deepak Gupta
Chiang Li
Youzhi Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Arthur B Pardee, Kenneth Anderson, Deepak Gupta, Chiang Li, Youzhi Li filed Critical Dana Farber Cancer Inst Inc
Priority to EP01997109A priority Critical patent/EP1387677A2/en
Priority to JP2002559028A priority patent/JP4244141B2/en
Priority to CA002428425A priority patent/CA2428425A1/en
Priority to AU2002248229A priority patent/AU2002248229B2/en
Publication of WO2002058694A2 publication Critical patent/WO2002058694A2/en
Publication of WO2002058694A9 publication Critical patent/WO2002058694A9/en
Publication of WO2002058694A3 publication Critical patent/WO2002058694A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Multiple myeloma and other hematologic tumors and/or malignancies can be treated by administration of a G1 and/or S phase drug, which is preferably β-lapachone, or a derivative or analog thereof, combined with a G2/M phase drug such as taxane derivative, which is advantageously paclitaxel. This combination of the G1 and/or S phase drug with the G2/M phase drug results in an unexpectedly greater than additive (i.e., synergistic) apoptosis in multiple myeloma cells. The invention includes methods of treating multiple myeloma by administering the combination of the G1 and/or S phase drug and the G2/M phase drug, pharmaceutical compositions comprising the combination of drugs used in these methods, as well as pharmaceutical kits.
PCT/US2001/049946 2000-11-07 2001-11-07 Method of treating hematologic tumors and cancers using beta lapachone WO2002058694A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP01997109A EP1387677A2 (en) 2000-11-07 2001-11-07 Method of treating hematologic tumors and cancers using beta lapachone
JP2002559028A JP4244141B2 (en) 2000-11-07 2001-11-07 Methods for treating blood tumors and blood cancers
CA002428425A CA2428425A1 (en) 2000-11-07 2001-11-07 Method of treating hematologic tumors and cancers
AU2002248229A AU2002248229B2 (en) 2000-11-07 2001-11-07 Method of treating hematologic tumors and cancers using beta lapachone

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24655200P 2000-11-07 2000-11-07
US60/246,552 2000-11-07

Publications (3)

Publication Number Publication Date
WO2002058694A2 WO2002058694A2 (en) 2002-08-01
WO2002058694A9 WO2002058694A9 (en) 2003-04-17
WO2002058694A3 true WO2002058694A3 (en) 2003-12-04

Family

ID=22931169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/049946 WO2002058694A2 (en) 2000-11-07 2001-11-07 Method of treating hematologic tumors and cancers using beta lapachone

Country Status (6)

Country Link
US (1) US20020169135A1 (en)
EP (1) EP1387677A2 (en)
JP (2) JP4244141B2 (en)
AU (1) AU2002248229B2 (en)
CA (1) CA2428425A1 (en)
WO (1) WO2002058694A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0977563B1 (en) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050222246A1 (en) * 1999-04-14 2005-10-06 Li Chiang J Beta-lapachone is a broad spectrum anti-cancer agent
US20050197405A1 (en) * 2000-11-07 2005-09-08 Li Chiang J. Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
US6816571B2 (en) * 2002-02-06 2004-11-09 L-3 Communications Security And Detection Systems Corporation Delaware Method and apparatus for transmitting information about a target object between a prescanner and a CT scanner
US6890950B2 (en) 2002-04-23 2005-05-10 Case Western Reserve University Lapachone delivery systems, compositions and uses related thereto
EP1545507A4 (en) * 2002-07-17 2009-04-22 Arqule Inc Activated checkpoint therapy and methods of use thereof
CN1759115A (en) 2002-08-23 2006-04-12 索隆-基特林癌症研究协会 Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO2004032923A1 (en) * 2002-10-11 2004-04-22 Dana-Farber Cancer Institute Inc Epothilone derivatives for the treatment of multiple myeloma
JP2007523191A (en) * 2004-02-20 2007-08-16 アークル・インコーポレーテツド Use of β-lapachone for the treatment of blood tumors
EP2033639A2 (en) 2004-02-20 2009-03-11 Arqule, Inc. Beta-lapachone for the treatment of colon cancer
CA2555950A1 (en) 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for the treatment of pancreatic cancer
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
WO2005082353A2 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treating or preventing cancer
EP1727536A1 (en) * 2004-02-23 2006-12-06 Arqule, Inc. Beta-lapachone and s-phase drug combinations for cancer treatment
US20050192247A1 (en) * 2004-02-23 2005-09-01 Li Chiang J. Method of treating cancers
NZ550665A (en) 2004-04-09 2010-05-28 Chugai Pharmaceutical Co Ltd Novel water-soluble prodrugs of camptothecin derivatives
CA2583700A1 (en) * 2004-08-11 2006-02-23 Arqule, Inc. Quinone prodrug compositions and methods of use
US8614228B2 (en) 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
WO2006024545A1 (en) * 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
TW200824692A (en) * 2006-08-21 2008-06-16 Arqule Inc Novel lapachone compounds and methods of use thereof
EP2152686B1 (en) 2007-04-30 2014-12-17 ArQule, Inc. Hydroxy sulfonate of quinone compounds and their uses
WO2009051752A1 (en) * 2007-10-16 2009-04-23 Arqule, Inc. Novel lapachone compounds and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004145A1 (en) * 1992-08-21 1994-03-03 Dana Farber Cancer Institute Treatment of human viral infections
WO1996033988A1 (en) * 1995-04-25 1996-10-31 Wisconsin Alumni Research Foundation Novel synthesis and use of beta-lapachone analogs
WO1997008162A1 (en) * 1995-08-24 1997-03-06 Dana-Farber Cancer Institute Beta-lapachone derivatives as antitumor agents
WO1997031936A2 (en) * 1996-02-20 1997-09-04 Wisconsin Alumni Research Foundation Novel ortho-naphthoquinone derivatives, novel synthesis therefor, and their use in the inhibition of neoplastic cell growth

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60031268T2 (en) * 1999-04-14 2007-05-24 Dana-Farber Cancer Institute, Inc., Boston METHOD AND COMPOSITION FOR THE TREATMENT OF CANCER

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004145A1 (en) * 1992-08-21 1994-03-03 Dana Farber Cancer Institute Treatment of human viral infections
WO1996033988A1 (en) * 1995-04-25 1996-10-31 Wisconsin Alumni Research Foundation Novel synthesis and use of beta-lapachone analogs
WO1997008162A1 (en) * 1995-08-24 1997-03-06 Dana-Farber Cancer Institute Beta-lapachone derivatives as antitumor agents
WO1997031936A2 (en) * 1996-02-20 1997-09-04 Wisconsin Alumni Research Foundation Novel ortho-naphthoquinone derivatives, novel synthesis therefor, and their use in the inhibition of neoplastic cell growth

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH. UNITED STATES 1 SEP 1995, vol. 55, no. 17, 1 September 1995 (1995-09-01), pages 3706 - 3711, ISSN: 0008-5472 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1 September 1995 (1995-09-01), PLANCHON S M ET AL: "Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response.", XP002241805, Database accession no. NLM7641180 *
GAZITT Y ET AL: "Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells.", INTERNATIONAL JOURNAL OF ONCOLOGY. GREECE OCT 1998, vol. 13, no. 4, October 1998 (1998-10-01), pages 839 - 848, XP008016801, ISSN: 1019-6439 *
LI Y ET AL: "Potent induction of apoptosis by beta - lapachone in human multiple myeloma cell lines and patient cells.", MOLECULAR MEDICINE, (2000 DEC) 6 (12) 1008-15., XP008016797 *
ZHANG W ET AL: "The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms.", LEUKEMIA: OFFICIAL JOURNAL OF THE LEUKEMIA SOCIETY OF AMERICA, LEUKEMIA RESEARCH FUND, U.K. ENGLAND SEP 1998, vol. 12, no. 9, September 1998 (1998-09-01), pages 1383 - 1391, XP002110654, ISSN: 0887-6924 *

Also Published As

Publication number Publication date
JP2008110995A (en) 2008-05-15
US20020169135A1 (en) 2002-11-14
WO2002058694A9 (en) 2003-04-17
JP4244141B2 (en) 2009-03-25
WO2002058694A2 (en) 2002-08-01
JP2004535363A (en) 2004-11-25
AU2002248229B2 (en) 2006-11-30
CA2428425A1 (en) 2002-08-01
EP1387677A2 (en) 2004-02-11

Similar Documents

Publication Publication Date Title
WO2002058694A3 (en) Method of treating hematologic tumors and cancers using beta lapachone
EP1181013A4 (en) Method and composition for the treatment of cancer
WO2004050033A3 (en) Method of treating cancers
BR9906581A (en) Process for administration of taxane encapsulated in liposomes
BR0115109A (en) Therapeutic agents and methods of their use for angiogenesis modulation
GT200900154A (en) DERIVATIVES OF 2,3-DIHYDROIMIDOZO [1,2-C] QUINIZOLINA SUBSTITUTED FOR USE IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
WO2004043377A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
WO2004103274A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
DK1169059T3 (en) Docetaxel in combination with rhuMAb HER2 for the treatment of cancers
WO2003097052A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
EP2425874A3 (en) Use of a vitamin D compound and an additional therapeutic agent for the treatment of cancer
BR0110837A (en) Combination Chemotherapy
TW200510367A (en) Novel lapachone compounds, their preparation, and the use thereof
WO2003082196A3 (en) Combination therapy using trefoil peptides
IS6558A (en) Mixed disease treatment with vasoconstrictor
ATE361746T1 (en) BOTANICAL EXTRACT WITH ANTI-CANCER ACTIVITY CONTAINING ISOLIQUIRITIGENIN
WO2001030335A3 (en) Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
BR0108728A (en) Pharmaceutical Combination Therapy, and, Method for Treating a Cancer.
WO2006113718A3 (en) Compositions for the treatment of neoplasms
EP1503748A4 (en) Drugs for mitigating taxane-induced neurotoxicity
BRPI0413410A (en) coadministration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
WO2000061141A3 (en) Methods and compositions for enhancing delivery of therapeutic agents to tissues
WO2005081972A3 (en) Maleiimide anti-tumor phosphatase inhibitors
UY26171A1 (en) PHARMACEUTICAL FORMULATION AND METHOD FOR THE TREATMENT OF LATE APPEARANCE DYSKINESIA

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 1/5-5/5, DRAWINGS, REPLACED BY NEW PAGES 1/6-6/6; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 2002559028

Country of ref document: JP

Ref document number: 2428425

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002248229

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001997109

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001997109

Country of ref document: EP